Search - tctmd.com

Displaying 41 - 49 of 49

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

Pulmonary Hypertension Type Predicts TAVR Outcome, Could Help Select Candidates

Yael L. Maxwell

August 05, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for August 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Pulmonary Hypertension Type Predicts TAVR Outcome, Could Help Select Candidates

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content